Susan Haigney

In a 2026 industry outlook interview, Laine Mello, Ecolab Life Sciences, explains how next-gen therapies, digitalization, and partnerships drive pharma agility.

In a 2026 industry outlook interview, Laine Mello, Ecolab Life Sciences, details how AI and Pharma 4.0 speed up discovery and production while navigating industry hurdles

At the Pharmapack Europe 2026 awards ceremony, Pharmapack announced it is expanding the event to Singapore in November 2026. This year’s award winners were also announced.

PharmTech spoke with Dexter Tjoa, CEO of Tjoapack, about how outside pressures are influencing supply chain and packaging decisions.

The half-day workshop will explore regulatory compliance and environmental sustainability.

PharmTech spoke with Dexter Tjoa, CEO of Tjoapack, about the past year and which trends might influence 2026 packaging decisions.

Industry experts discuss the standout packaging trends from 2025 that will influence the industry’s future.

Contract development and manufacturing organizations offer specialized services to help sponsor companies develop drug products that better serve the unique needs of patients.

The company will be highlighting its PharmaGuard recyclable blister solution, MedGuard line, and MedHub procurement service.

AI and machine learning are helping pharmaceutical scientists more efficiently develop innovative and novel treatments for a range of disease areas.

AI and machine learning may be the ideal tools to evaluate patient data and predict ideal treatment options.

The company is adding a second production line at its Etten-Leur facility in The Netherlands to meet customer needs.

The CRDMO’s new facility will double chemistry capacity for drug discovery research and scale-up projects.

Dr. Jennifer Levin Carter, founder and CEO of Medzown, discusses what makes precision medicine different from personalized medicine and what how challenges faced in this evolving field can be overcome.

Arthur Tzianabos, CEO, Lifordi Immunotherapeutics, spoke with PharmTech about the company’s immune-directed antibody-drug conjugate (ADC) strategy, the benefits of VISTA-targeted ADCs in drug delivery, and Lifordi’s plans at the JP Morgan Healthcare Conference.

Elisabeth Gardiner, CSO of Tevard Biosciences, discusses how transfer RNA is impacting the development of gene therapies for diseases with unmet needs.

The company’s new AI agent automates labor-intensive processes involved in trial document management.

The move brings Amgen first-in-class, small molecule-targeted protein degraders for oncology.

Laine Mello, director of marketing at Ecolab Bioprocessing, reflects on how the use of digital technologies expanded in the pharma industry in 2025 and how new complex molecules will continue to drive innovation in 2026.

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals will receive advisory services and funding from UKRI Innovate UK and Canada’s NRC IRAP to develop next-generation genetic medicines.

Raj Puri, chief commercial officer at Argonaut Manufacturing, talks about how navigating the pressure to respond to tariffs with investments and keeping a robust and qualified staff are key moves in the new year.

Meri Beckwith, Co-CEO of Lindus Health, provides a look at how trends that developed in 2025 will impact the pharmaceutical industry in 2026.

FUJIFILM Irvine Scientific has changed its name to FUJIFILM Biosciences to better align with the company’s work in cell culture media manufacturing.

ROSS’s DCB-5 Double Cone Tumble Blender can handle high-density materials and provides repeatable homogeneity and powder blending properties, according to the company.

PharmTech spoke with Campbell Bunce, chief scientific officer, Abzena to find out which trends in 2025 impacted the industry the most.

In this overview, PharmTech takes a look back at significant news in the development and approval of cancer treatment in 2025.

David Basile, VP Technical Operations, Americas, Hovione, highlights some common mistakes made by pharmaceutical companies when maintaining manufacturing facilities and equipment.

Pharmaceutical Technology®’s quality experts, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs company, and Siegfried Schmitt, PhD, vice president, Technical at Parexel discuss how pharmaceutical manufacturing training has evolved over the years and how the influx of new facilities is demanding a skilled workforce.

André Cerbe, CEO of Schlafender Hase, spoke with Pharmaceutical Technology® about the disruptions the pharma industry faced in 2025 and how digital workflows will be key for success in 2026.

How will plans to rework medicines legislation in the European Union impact drug development, innovation, and market exclusivity?